PHILADELPHIA (AP) — Vice President Joe Biden launched a “moonshot” initiative Friday to hasten a cure for cancer, aiming to use his final year in office to break down barriers in the medical world he says are holding back progress on eradicating the dreaded disease.
Biden chose Penn Medicine’s Abramson Cancer Center in Philadelphia as his venue to call attention to the institute’s pioneering efforts on immunotherapy, in which a patient’s own immune system is deployed against cancer cells. After touring the facility’s Center for Advanced Cellular Therapeutics, Biden sat down with doctors, researchers and academics to discuss recent advances.
“You’re on the cusp of some phenomenal breakthroughs,” he said. “In my terms – not your medical terms – we are at an inflection point in the fight against cancer.”
With barely a year left, Biden has yet to lay out exactly what he’ll do that hasn’t been done in the half century since President Richard Nixon declared war on cancer. But Biden said in addition to pushing for more funding, he would use his influence to “break down silos” he says are pervasive throughout the sprawling and fragmented world of cancer
- Doctors worry over women going for cleanshaven ‘Barbie doll look’
- Billionaire Paul Allen donates $1M to build housing for homeless in Columbia City
- The sorrow of Steak ’n Shake VIEW
- N. Carolina sheriff: No sign of hate crime in woman's death
- Grizzly kills mountain biker near Glacier National Park
Most Read Stories
Since declaring his “moonshot” in October, Biden has been searching for answers about what’s holding back a cure, with all the meticulousness of a physician diagnosing disease. His conclusion: The hold-up, in large part, lies in the cancer world itself.
Meeting with scientists Friday, Biden recalled his grandfather’s adage that the world has three kinds of politics: church politics, labor politics and regular politics.
“I hope you’re not offended, but there are four kinds of politics in America. There’s cancer politics,” Biden said. He deemed that particular flavor even more vexing than the rest.
But Jim Greenwood, CEO of BIO, which represents the biotech industry, said there’s a reason why organizations developing treatments must keep some information to themselves.
“There are prioprietary interests, and the model for developing drugs in the U.S. is done by the private sector,” Greenwood said. “That means competition, and there’s a lot of benefit to that.”
Still, Biden has described a system in which competition, territorialism and “stove-piping” of information leave researchers and their discoveries cloistered in their own corners. His campaign this year will work to encourage more data-sharing about patient data and treatment outcomes.
“My hope is that I can be a catalyst, to oversimplify it, to get everybody on the same page,” Biden said.
A key focus will be promising advances such as immunotherapy. At the cancer center Biden visited Friday, researchers are exploring what’s known as chimeric antigen receptor technology, in which a patient’s immune cells are engineered outside of their body to hunt for tumors, then infused back into the patient’s body. The White House said 250 patients have been treated with the approach, with early promising results.
Another priority for the vice president is to further “precision medicine,” which personalizes treatments based on the genetic makeup of a patient’s tumors. Cancer researchers who met with Biden recently said he was intrigued by the possibilities for improving prevention and early detection.
Biden planned to continue the effort next week by convening global cancer experts at the World Economic Forum in Davos, Switzerland. Then he’ll chair a series of meetings with Cabinet secretaries in about ways to boost federal funds.
For Biden, the emotional undertones of his mission are difficult to avoid. After his 46-year-old son, Beau Biden, died from brain cancer in May, Biden entered a period of painfully public mourning, followed eventually by his decision not to enter the presidential race.
“This is still a blow that he’s still recovering from,” said former Sen. Ted Kaufman, a Biden confidante for many decades. “He’s in his problem-solving mode. He’s more comfortable in this area because of his desire to eliminate this thing that caused him so much damage.”
When Biden, in a Rose Garden speech, announced a bid “to cure cancer,” eyebrows were raised. Some wondered whether Biden was unduly raising expectations.
“I’m an eternal optimist, but I’m not going to go around saying we’re going to cure cancer in five years. That’s just not realistic,” said Dr. George Demetri, a Harvard Medical School professor and researcher at the Dana-Farber Cancer Institute who met with Biden’s staff.
Biden acknowledged that some cancers can’t be cured, insisting he wasn’t naive. But he said he thought it was possible to double the rate of scientific advances.
Because cancer takes hundreds of forms, it can’t be eradicated by any single advance. But immense progress has been made recently. Survival rates for most cancers are increasing, although the American Cancer Society still predicts nearly 1.7 million new cancer cases this year and nearly 600,000 deaths.
Lederman reported from Washington.
Reach Josh Lederman on Twitter at http://twitter.com/joshledermanAP